[L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].
We report a 34-year-old woman with juvenile parkinsonism who had been treated with five tablets daily of l-dopa/benserazide (100 mg/25 mg). She became pregnant in May 1995 and continued the same treatment. She delivered a healthy boy (3,798 g, 52 cm) with Apgar scores of 9 at 38 weeks gestation by normal delivery. In animal study, there is a report of teratogenicity (bone abnormality) of l-dopa/benserazide in rabbits at doses of 30 mg/kg and 120 mg/kg. However, there have been several reports of uneventful delivery of normal children in patients with juvenile parkinsonism who had been treated with l-dopa/decarboxylase inhibitor (DCI) during pregnancy. There seems to be no firm reason to avoid pregnancy during the treatment of l-dopa/DCI or to withhold l-dopa/DCI during pregnancy.
Arai
H
H
Department of Neurology, School of Medicine, Chiba University.
Shinotoh
H
H
Hattori
T
T
D000328:Adult; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001545:Benserazide / Q000008:administration & dosage*; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011817:Rabbits
D000978:Antiparkinson Agents; D002257:Carbonic Anhydrase Inhibitors; D007980:Levodopa; D001545:Benserazide